Beacon gene therapy becomes the first to win a pivotal XLRP trial

X-linked retinitis pigmentosa, commonly shortened to XLRP, is an inherited retinal disease that primarily affects males, and it is caused by mutations in the retinitis pigmentosa GTPase regulator gene, known as RPGR. The condition damages rod and cone photoreceptors in the retina, so patients typically begin with night blindness and difficulty seeing in low light, then experience narrowing of the peripheral visual field and, eventually, severe vision loss. At present there are no approved pharmaceutical treatments or gene therapies specifically for XLRP, a gap that has left hundreds of thousands of patients worldwide without a way to slow the loss of their sight.

Beacon Therapeutics, a clinical-stage biotechnology company based in London and Cambridge, Massachusetts, has been trying to change that picture. The company is a portfolio company of Syncona Limited, the London-listed life sciences investor whose shares trade under the ticker SYNC.L. On September 21, 2026, Beacon reported that its one-time subretinal gene therapy, laruparetigene zovaparvovec, which the company calls laru-zova, had met the FDA-endorsed primary endpoint in the pivotal Phase II/III VISTA trial. The readout landed as a first for the field: according to the company, VISTA is the first and only pivotal trial in XLRP to achieve its primary endpoint.

The design of the study was concrete. VISTA, registered as NCT04850118, is a randomized, controlled, masked and multicenter study that evaluated 85 male patients aged 12 to 48 whose XLRP was caused by RPGR mutations. Participants received a single subretinal administration of either a high dose of 6.8 E+11 vector genomes per eye or a low dose of 3.7 E+11 vector genomes per eye, or they were assigned to an untreated control group, and all were followed for 12 months. The therapy is designed to deliver a functional copy of the RPGR ORF15 gene so that photoreceptors can produce a full-length protein and restore the natural function of both rods and cones.

Key Facts

The primary endpoint measured the proportion of participants who gained at least 15 letters of low-luminance visual acuity, or LLVA, at Month 12. According to the topline data, 31.0 percent of patients in the high dose group met that threshold with a p value of 0.0019, and 24.1 percent in the low dose group met it with a p value of 0.0106, while no participants in the untreated control group achieved the same improvement. Reuters reported on September 21, 2026 that the therapy improved the ability to read in low-light conditions, with no control group participants reaching the same level.

Secondary measures offered supportive trends. On microperimetry, the least-squares mean difference in mean macular sensitivity versus the untreated control group was 1.201 decibels in the high dose group, with a p value of 0.0614, and 1.312 decibels in the low dose group, with a p value of 0.0405. The proportion of participants achieving at least a 10-letter LLVA improvement reached 48.3 percent in the high dose group, 58.6 percent in the low dose group and 3.7 percent in the control group.

Safety data were described as favorable and consistent with earlier studies. Ocular treatment-emergent adverse events were predominantly mild to moderate and largely attributed to the surgical procedure. Laru-zova-related treatment-emergent adverse events were reported in 25 percent of high dose participants and 38 percent of low dose participants, and two ocular serious adverse events occurred in the low dose group, both attributed to the surgery.

Clinical Trials Arena reported on September 21, 2026 that Beacon will seek approval for laru-zova after the Phase III VISTA trial met its endpoints. The company has said the results expand evidence across five years of clinical experience and 110 treated participants, building on the earlier HORIZON, SKYLINE and DAWN trials. Laru-zova is also being investigated in the LANDSCAPE trial, registered as NCT07174726.

Analysis

What this really means is that Beacon has produced the first statistically significant pivotal win in a disease where larger and better-capitalized developers previously stumbled. The Catalyst Brief reported on September 21, 2026 that XLRP has seen high-profile setbacks from Biogen and Johnson and Johnson, so the result suggests that endpoint selection and construct design may matter as much as the broader promise of retinal gene therapy. Biogen's Phase II/III XLRP gene therapy trial missed its primary endpoint in 2021 using a measure of retina sensitivity, and Johnson and Johnson suffered a Phase III setback in 2025 with a study that assessed patients' ability to navigate a virtual maze. Johnson and Johnson's partner MeiraGTx has since bought back that gene therapy and plans to push for approval this year despite the unsuccessful trial.

Beacon Chief Executive Officer Lance Baldo pointed to trial design as one reason VISTA succeeded, centering visual acuity under low light. He also described codon optimization as the company's key technical differentiator. Baldo said the native RPGR gene is very unstable, and Beacon sought to address that by altering codons in the genetic sequence without changing the resulting protein's structure, an approach intended to preserve a stable full-length gene that can produce functional protein in photoreceptors.

Robert Sisk, MD, of the Cincinnati Eye Institute and a professor of ophthalmology at the University of Cincinnati, said Beacon selected endpoints that would best capture improvements that matter to patients, particularly their ability to see in low-light conditions, which he called one of the most challenging aspects of living with XLRP. He added that achieving high statistical significance in a 15-letter or greater improvement in LLVA demonstrates a clinically meaningful and consistent treatment effect in VISTA.

The bigger picture here is that the readout gives regulators a clear, patient-relevant measure to assess, and it gives Beacon a credible path toward becoming first in disease. RTTNews reported on September 21, 2026 that Syncona Limited announced its portfolio company Beacon reported positive topline results from the pivotal VISTA Phase 2/3 trial, and that the trial met its FDA-endorsed primary endpoint. RTTNews also noted that Syncona shares closed on the prior Friday at GBp 111.60, down 0.18 percent on the London Stock Exchange, a reminder that the market had not yet priced in a transformational outcome before the data landed.

Why It Matters

For patients and families, the significance is direct. XLRP begins with night blindness and progresses to narrowing of the peripheral field of vision and severe vision loss, and there is currently no approved treatment that can slow that trajectory. A one-time therapy that restores some ability to see in low light would address one of the most disabling features of the disease, because low-light and nighttime function is precisely what the condition erodes first.

Jason Menzo, chief executive officer of the Foundation Fighting Blindness, said this is the first pivotal study of a potential treatment for XLRP to achieve its primary endpoint with statistical significance. That framing matters because the field has been waiting for a registration-quality result that validates both the biology and the trial methodology.

The result also carries commercial weight. A GlobalData report cited by Clinical Trials Arena predicts that cases of RP across the 16 major pharmaceutical markets will rise from 1.04 million in 2024 to 1.08 million by 2029. A first-in-disease gene therapy with a pivotal win would sit at the front of that growing population, and Beacon has said it is keeping its options open on whether to commercialize alone or seek partners in some markets. The company employs 80-plus people, so partnership decisions will shape how quickly any approved therapy reaches patients.

Next Up

Beacon plans to begin pre-submission discussions with global regulatory authorities, with the initiation of a rolling Biologics License Application submission planned for later in 2026. Reuters reported on September 21, 2026 that Beacon plans to start and finish a rolling biologics license application to the FDA before the year's end, while also pursuing approval in the European Union and the United Kingdom.

Additional VISTA data are expected to be presented at a late-breaking session during the American Academy of Ophthalmology meeting in New Orleans from October 9 to 12, 2026. The therapy has received several designations from the FDA and the European Medicines Agency, and those designations, together with the new efficacy and safety dataset, will frame the company's conversations with regulators in the months ahead.